Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
3
×
boston blog main
boston top stories
depression
3
×
life sciences
major depressive disorder
national blog main
national top stories
blackstone group
clinical trials
david goldstein
epilepsy
essential tremor
kiran reddy
neuroscience
new york blog main
new york top stories
perimenopausal depression
praxis precision medicines
sage therapeutics
steven petrou
aligos therapeutics
antisense oligonucleotide
baker brothers life sciences
benzodiazepine
benzodiazepines
biogen
biotech ipos
blackstone life sciences
blepharitis
brexanalone
cavion
cephalgia
chronic hepatitis b virus
clinical data
columbia university
demodex blepharitis
epi4k
eventide asset management
What
drugs
medicines
praxis
precision
research
aims
approval
backed
biotechs
brexanalone
cause
central
ceo
cns
depression
disorder
drug
emerged
epilepsy
fda
genes
genetic
hits
hour
infusion
ipos
kept
leads
links
marcio
mark
medical
mutations
nervous
neuro
new
phase
postpartum
ppd
prep
Language
unset
Current search:
depression
×
boston
×
@xconomy.com
3 years ago
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
@xconomy.com
3 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
5 years ago
Sage Hits Mark in Postpartum Depression Phase 3 Trial, Stock Surges
